Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.

导出 OA

翻译打印收藏纠错

作者： Mark E,Layton ^[1] ; Jeffrey C,Kern ^[1] ; Timothy J,Hartingh ^[1] ; William D,Shipe ^[1] ; Izzat,Raheem ^[1] ; Monika,Kandebo ^[2] ; Robert P,Hayes ^[3] ; Sarah,Huszar ^[4] ; Donnie,Eddins ^[4] ; Bennett,Ma ^[5] ; Joy,Fuerst ^[6] ; Gordon K,Wollenberg ^[7] ; Jing,Li ^[8] ; Jeff,Fritzen ^[8] ; Georgia B,McGaughey ^[9] ; Jason M,Uslaner ^[2] ; Sean M,Smith ^[2] ; Paul J,Coleman ^[1] ; Christopher D,Cox ^[1]

作者单位： Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. ^[1] Neuroscience, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. ^[2] Structural Chemistry, Merck & Co., Inc., Boston, Massachusetts 02115, United States. ^[3] In Vivo Pharmacology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. ^[4] Pharmacokinetics, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. ^[5] Discovery Pharmaceutical Sciences, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. ^[6] Nonclinical Drug Safety, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. ^[7] Discovery Process Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. ^[8] Chemistry Modeling and Informatics, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. ^[9]